MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Leucine-rich repeat kinase 2(LRRK2)"

  • 2025 International Congress

    Investigating the cellular consequences of the G2385R LRRK2 variant

    P. Lewis, S. Herbst (London, United Kingdom)

    Objective: The objective of this study is to characterise the biochemical and cellular impact of the G2385R coding variant in LRRK2, a risk variant for…
  • 2025 International Congress

    Association of sequence alterations in the promoter region of the RAB7L1 gene with lysosomal hydrolase activity in blood and reduced risk of Parkinson disease

    K. Basharova, A. Bezrukova, K. Senkevich, G. Baydakova, I. Miliukhina, A. Timofeeva, E. Zakharova, S. Pchelina, T. Usenko (Gatchina, Russian Federation)

    Objective: The aim of this case-control study was to examine the association between SNPs located in the promoter region of the RAB7L1 gene and Parkinson's…
  • 2025 International Congress

    Lysosomal Lipid Dysregulation in Parkinson’s Disease: Genetic and Medication Effects in CSF Metabolomics

    J. Suh, R. Maciuca, E. Macklin, S. Davis, J. Kluss, N. Xia, H. Yazd, M. Schwarzschild, S. Huntwork-Rodriguez (South San Francisco, USA)

    Objective: Define lipid signatures in sporadic, LRRK2, and GBA1 PD and pre-manifest carriers and assess medication impacts. Background: Lysosomal dysfunction contributes to PD, particularly in…
  • 2025 International Congress

    Large-scale genetic characterization of Parkinson’s disease in the African and African admixed populations

    F. Akcimen (Bethesda, USA)

    Objective: The influence of genetics has been primarily studied in European populations, limiting our understanding of the genetic landscape of PD in the African and…
  • 2025 International Congress

    Evaluation of the Pharmacodynamic Effects of BIIB122/DNL151 in Participants with LRRK2 mutation-driven Parkinson’s disease (BEACON Study)

    J. Kluss, S. Huntwork-Rodriguez, D. Jennings, S. Ota, R. Maciuca, J. Alkabsh, S. Davis, J. Suh, M. Schwarzschild, K. Fraser, R. Llorens-Arenas, C. Ho, P. Chin (South San Francisco, USA)

    Objective: To characterize the biomarker effects of BIIB122/DNL151 in participants with LRRK2 pathogenic mutations diagnosed with Parkinson’s disease (LRRK2-PD). Background: BIIB122/DNL151 is a CNS-penetrant small…
  • 2025 International Congress

    The Role of Polygenic Background and APOE E4 in Monogenic and Idiopathic Parkinson’s Disease

    M. Kmiecik, M. Holmes, P. Fontanillas, G. Riboldi, R. Schneider, J. Shi, A. Guan, S. Tat, K. Stagaman, J. Gottesman, D. Hinds, J. Tung, S. Aslibekyan, L. Norcliffe-Kaufmann (Sunnyvale, USA)

    Objective: To assess the impact of 1) polygenic risk scores (PRS) on monogenic Parkinson’s disease (PD) risk and time to diagnosis and 2) APOE E4…
  • 2025 International Congress

    The Moroccan LRRK2 Registry: Building Resources to Investigate the Penetrance and Phenotype of LRRK2 in North Africans

    Y. Razouqi, M. Megraoui, F. Belahsen, L. Bouguenouch, B. Elmakhzen, H. Ouhabi, J. Aasfara, Y. Zaid, A. Atpu, L. Khalki, M. Rizig (Casablanca, Morocco)

    Objective: The Moroccan LRRK2 Registry aims to establish a comprehensive database integrating clinical data and biosamples to provide valuable insights into the penetrance, phenotype, and…
  • 2025 International Congress

    Long-term outcomes of subthalamic Deep Brain Stimulation in LRRK2 patients

    C. Lazaro Hernandez, A. Garrido Pla, A. Sanchez Gomez, A. Cadena Fernandez, J. Bejarano Hernandez, F. Valldeoriola Serra (Barcelona, Spain)

    Objective: To compare the basal characteristics and postoperative clinical outcomes of LRRK2 mutation carriers and idiopathic Parkinson’s disease patients treated with subthalamic deep brain stimulation…
  • 2025 International Congress

    Phase 1 and 1b Pharmacodynamic Data Support Central Modulation of Lysosomal Pathways With BIIB122/DNL151, a LRRK2 Kinase Inhibitor: Insights for the LUMA Trial

    K. Fraser, A. Lang, L. Kalia, R. Hauser, J. Greenamyre, Y. Moroishi, J. Kluss, B. Hersh, K. Ferber, R. Maciuca, C. Paián-Ruiz, R. Llorens-Arenas, D. Jennings, S. Huntswork-Rodriguez, D. Graham (Tampa, USA)

    Objective: Evaluate the effects of BIIB122/DNL151 treatment on CSF levels of pRab10, a biomarker of CNS LRRK2 modulation, in a Phase 1 study in healthy…
  • 2025 International Congress

    Impact of Constipation on Motor and Non-Motor Symptoms in G2019s Lrrk2 Parkinson’s Disease A Retrospective Study

    A. Agrebaoui, R. Zouari, A. Mousli, R. Amouri, A. Rachdi, F. Nabli, Z. Saied, S. Ben Sassi (Tunis, Tunisia)

    Objective: This study aimed to investigate the association between constipation and the severity of motor and non-motor symptoms in PD patients with the G2019S LRRK2…
  • 1
  • 2
  • 3
  • …
  • 19
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Life expectancy with and without Parkinson’s disease in the general population
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley